These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25217217)

  • 1. An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease).
    De Haro J; Bleda S; Acin F
    Int J Cardiol; 2014 Dec; 177(2):529-31. PubMed ID: 25217217
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of bosentan in digital ischemic ulcers.
    Todoli Parra JA; Hernández MM; Arrébola López MA
    Ann Vasc Surg; 2010 Jul; 24(5):690.e1-4. PubMed ID: 20579585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of bosentan in the treatment of digital ulcers secondary to thromboangiitis obliterans].
    Prior Á; Rodriguez-Muguruza S; Sanint J; Olivé A
    Med Clin (Barc); 2015 Jul; 145(1):44. PubMed ID: 25433787
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of bosentan in the treatment of ischemic lesions in a case of thromboangiitis obliterans (Buerger disease): a case report.
    Palomo-Arellano A; Cervigón-González I; Torres-Iglesias LM
    Dermatol Online J; 2011 Jul; 17(7):4. PubMed ID: 21810389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.
    Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Blanco-Sánchez G; Rodríguez-Mateos ME; Linares-Barrios M
    Dermatol Ther; 2015; 28(3):135-9. PubMed ID: 25649782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thromboangiitis obliterans (Buerger's disease): update 2015].
    Klein-Weigel P; Volz TS; Richter J
    Dtsch Med Wochenschr; 2015 Oct; 140(20):1486-9. PubMed ID: 26445249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.
    De Haro J; Acin F; Bleda S; Varela C; Esparza L
    BMC Cardiovasc Disord; 2012 Feb; 12():5. PubMed ID: 22333218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation study of predictive value of capillaroscopic skin ulcer risk index (CSURI) in scleroderma patients treated with bosentan.
    Sebastiani M; Manfredi A; Cestelli V; Praino E; Cannarile F; Giuggioli D; Colaci M; Ferri C
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S196. PubMed ID: 26242501
    [No Abstract]   [Full Text] [Related]  

  • 9. Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors.
    Abeles AM; Nicolescu M; Pinchover Z; Abeles M
    Vascular; 2014 Aug; 22(4):313-6. PubMed ID: 24000082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
    Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
    J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
    García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
    Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboangiitis obliterans (Buerger's disease).
    Klein-Weigel PF; Richter JG
    Vasa; 2014 Sep; 43(5):337-46. PubMed ID: 25147010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboangiitis obliterans: an old disease in need of a new look.
    Adar R; Papa MZ; Schneiderman J
    Int J Cardiol; 2000 Aug; 75 Suppl 1():S167-70; discussion S171-3. PubMed ID: 10980358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
    Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
    Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.
    Le Joncour A; Soudet S; Dupont A; Espitia O; Koskas F; Cluzel P; Hatron PY; Emmerich J; Cacoub P; Resche-Rigon M; Lambert M; Saadoun D;
    J Am Heart Assoc; 2018 Dec; 7(23):e010677. PubMed ID: 30571594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thromboangiitis obliterans (Buerger disease) discovered by symptoms of arthralgia in a young woman].
    Kovacsovics-Bankowski M; Gerster JC
    Praxis (Bern 1994); 1997 Dec; 86(49):1945-8. PubMed ID: 9480517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Images in clinical medicine. Thromboangiitis obliterans (Buerger's disease).
    Sims JR; Hanson EL
    N Engl J Med; 1998 Sep; 339(10):672. PubMed ID: 9725925
    [No Abstract]   [Full Text] [Related]  

  • 18. [Deep vein thrombosis revealing thromboangiitis obliterans or Buerger's disease].
    Ben Salah R; Frikha F; Snoussi M; Saidi N; Bahloul Z
    J Mal Vasc; 2014 Dec; 39(6):445-7. PubMed ID: 24976275
    [No Abstract]   [Full Text] [Related]  

  • 19. Winiwarter-Buerger disease ('thromboangiitis obliterans') with cerebral involvement.
    Drake ME
    JAMA; 1982 Oct; 248(15):1870-2. PubMed ID: 7120607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic ulcerations in the upper and lower extremities. Thromboangiitis obliterans (Buerger disease).
    Zellman GL; Lin MT; Rosen T
    Arch Dermatol; 1998 Aug; 134(8):1019-20, 1023. PubMed ID: 9722735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.